Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 6/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | LITAF | Q99732 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993589 | 0.90 | TDP1 (0.47) | TDP1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL4981984 | 0.85 | TDP1 (0.48) | TDP1MEN1ALDH1A1KMT2ATDP2 | |
| SCHEMBL240616 | 0.84 | TDP1 (0.64) | TDP1PDE5ATDP2ABCC1 | |
| SCHEMBL29911473 | 0.84 | TDP1 (0.64) | TDP1PDE5ATDP2ABCC1 | |
| SCHEMBL15602618 | 0.84 | TDP1 (0.47) | TDP1MEN1KMT2APDE5ATDP2 | |
| SCHEMBL13996247 | 0.84 | TDP1 (0.40) | TDP1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL243190 | 0.83 | TDP1 (0.47) | TDP1ALDH1A1KMT2APDE5ATDP2 | |
| SCHEMBL241722 | 0.83 | TDP1 (0.46) | TDP1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL16501190 | 0.83 | TDP1 (0.46) | TDP1MEN1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL243528 | 0.82 | TDP1 (0.52) | TDP1MEN1ALDH1A1KMT2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468366-B2 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-12-23 | — | — | US | claimed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | claimed |
| US-20050009825-A1 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-01-13 | — | — | US | claimed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | claimed |
| US-7468366-B2 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050009825-A1 | Cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-01-13 | — | — | US | disclosed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009825-A1 | Cytotoxic agents | TOP1, TOP2A, TOP2B | TDP1 7/4885MEN1 1748/4885ALDH1A1 1935/4885 |
| US-20080090831-A1 | CYTOTOXIC AGENTS | TOP1, TOP2A, TOP2B | TDP1 7/4885MEN1 1748/4885ALDH1A1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.